Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population

Last updated: May 30, 2025
Sponsor: Ningbo No. 1 Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Primary Biliary Cholangitis

Diabetes Mellitus, Type 2

Treatment

Observational

Clinical Study ID

NCT06984510
2025-070RS-01
MR-33-25-026098
  • Ages 20-90
  • All Genders

Study Summary

The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Abdominal ultrasound data available in annual health check-up records

  2. At least one of the following five metabolic indicators recorded annually:

(1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c)

Exclusion

Exclusion Criteria:

  1. Age <20 or >90 years

  2. Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis Binfection)

  3. Type 2 diabetes mellitus at baseline

  4. Missing baseline data for any of the following variables: systolic blood pressure,albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, meancorpuscular volume, uric acid, fasting plasma glucose, and red cell distributionwidth (RDW)

Study Design

Total Participants: 2720
Treatment Group(s): 1
Primary Treatment: Observational
Phase:
Study Start date:
April 01, 2025
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000

    Ningbo, Zhejiang 315000
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.